Programs currently tracked for this institution in the public Translational Deal Radar dataset.
Anti-CD22 CAR NK Cells is flagged as a platform signal because it has an active early-phase oncology cell-therapy trial at Allife Medical Science and Technology Co., Ltd., with a possible patent signal linked through modality_match. Manual review is still required.
Early Phase1 · Unknown
View assetanti-Mesothelin Car NK Cells is flagged as a platform signal because it has an active early-phase oncology cell-therapy trial at Allife Medical Science and Technology Co., Ltd., with a probable patent signal linked through modality_match. Manual review is still required.
Early Phase1 · Unknown
View asset